Copper Complex Halts Botulinum Neurotoxin Poisoning
|
By HospiMedica International staff writers Posted on 12 Jun 2017 |
A new study describes how a readily available metal salt could provide a new therapy for Botulinum Neurotoxin type A (BoNT/A), the most common and deadly cause of human botulism.
Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.
They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.
“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”
BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.
Related Links:
Scripps Research Institute
Boston University
Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.
They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.
“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”
BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.
Related Links:
Scripps Research Institute
Boston University
Latest Critical Care News
- Scotland Adopts Respiratory Infection Control Guidance Informed by Aerosol Research
- Hospital Safety Program Linked to 65% Reduction in MRSA Bloodstream Infections
- Wearable Microneedle Device Aims to Enable Remotely Managed Pain Relief
- Octopus-Inspired Patch Improves Adhesion for Transdermal Drug Delivery
- Multimodal AI System Tracks Early Warning Signs of Mental Health Crisis
- Self-Folding Paper Sensor Conforms to Body Without Straps or Adhesives
- Patch-Based Therapy Promotes Myelin Repair in Multiple Sclerosis
- Rapid EHR Surveillance Helps Protect High-Risk Patients During Heat Waves
- Remote Cardiac Device Monitoring System Shows Safety and Cost Benefits
- Ambulatory ECG Monitor Improves Arrhythmia Detection in Syncope
- New Prediction Tool Supports Confident Prescribing of Heart Failure Medicines
- Machine Learning Models Identify Higher-Risk Pregnancies Earlier in Care
- Wearable Hormone Monitor Enables At-Home Detection of Primary Aldosteronism
- Contactless AI Tool Detects Hypertension and Diabetes from Facial Video
- AI Tool Predicts Bladder Cancer from Electronic Health Records
- Personalized Neuromodulation System Receives FDA Clearance for PTSD Treatment
Channels
Artificial Intelligence
view channel
Explainable AI Tool Identifies High-Risk Patients Before Heart Attack Reperfusion
Intramyocardial hemorrhage is bleeding within the heart muscle that can occur after blood flow is restored during heart attack treatment. It affects about 40% of patients treated for ST-segment elevation... Read more
AI Tools Show Potential to Detect Subtle Signs of Interval Breast Cancer
Interval breast cancers, diagnosed after a negative screening mammogram and before the next scheduled exam, remain an important measure of screening performance and are often more aggressive.... Read moreSurgical Techniques
view channel
FDA Clears Integrated Platform for Real-Time Cardiac Imaging and Catheter Guidance
Catheter-based treatment of cardiac arrhythmias relies on precise, real-time visualization and navigation for safe, accurate therapy delivery. Yet electrophysiology teams often use separate imaging, mapping,... Read more
New Microcatheter Enhances Lesion Crossing in Complex Coronary Interventions
Crossing resistant coronary lesions during percutaneous coronary intervention can be hindered by tortuous or calcified anatomy, delaying therapy and complicating device delivery. Many microcatheters rely... Read more
Integrated Perioperative Care Model Improves Recovery in Older Surgical Patients
Older adults undergoing major surgery often experience anxiety and depression that can slow rehabilitation and worsen functional recovery. Many also take central nervous system–active medications that... Read more
Integrated PET/MRI and EEG Improves Presurgical Lesion Localization in Pediatric Focal Epilepsy
Focal epilepsy, in which seizures arise from a discrete brain region, requires precise lesion localization before surgery. Many children have negative or inconclusive magnetic resonance imaging (MRI),... Read morePatient Care
view channel
Virtual Reality Helps Claustrophobic Patients Complete Cardiac PET/CT Scans
Anxiety and claustrophobia—intense fear of confined spaces—often prevent patients from completing cardiac positron emission tomography/computed tomography (PET/CT). Aborted scans delay diagnosis, consume... Read more
Weighted Blankets Reduce Anxiety in Hospitalized Adults
Anxiety is common among hospitalized adults and can impair recovery, disrupt sleep, and worsen mental health. Although clinicians often use nonpharmacologic strategies, bedside options that act quickly... Read moreMedical Imaging
view channel
Noninvasive MRI Spectroscopy Classifies Pediatric Medulloblastoma Molecular Subgroups
Medulloblastoma, the most common malignant pediatric brain tumor, requires precise molecular classification to guide therapy and predict outcomes. Current subgrouping typically depends on surgical sampling... Read more
Noninvasive Optical Test Detects Hidden Tissue Damage in Pelvic Organ Prolapse
Pelvic organ prolapse (POP) occurs when weakened pelvic-support tissues allow the bladder, uterus, or rectum to descend. Although it affects millions of women, the condition remains under-characterized... Read moreHealth IT
view channel
Registry-Driven Digital Outreach Boosts Use of Heart Failure Medicines
Heart failure affects more than 64 million people worldwide and is linked to high mortality, reduced quality of life, and heavy healthcare use. Although sodium-glucose cotransporter 2 inhibitors are proven... Read more
Nurse-Coordinated Care Model Improves Heart Failure Outcomes
Heart failure imposes heavy mortality, morbidity, and cost burdens worldwide, yet proven therapies remain underused in routine practice. This inadequate uptake contributes to preventable hospitalizations... Read morePoint of Care
view channel
Microneedle Patch Enables At-Home Monitoring of Acute Kidney Injury
Kidney disease is often silent in its early stages, making timely detection difficult outside clinical settings. Early biomarkers such as neutrophil gelatinase–associated lipocalin can require blood draws... Read more
Ultrathin Metasurface Could Bring Quantitative Phase Imaging to Portable Devices
Point-of-care imaging often depends on bulky optical systems that have difficulty visualizing nearly transparent cells and tissues without staining. These limitations can slow diagnosis and restrict use... Read moreBusiness
view channel
Robotic Single-Port System Gains CE Mark for Transvaginal Gynecologic Procedures
Intuitive (Sunnyvale, CA, USA) announced that it has received CE mark approval for use of the da Vinci SP Single Port surgical system in transvaginal gynecologic procedures, marking the first such indication... Read more







